CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLYM CLIMB BIO INC

Pre-Mkt 08-07 07:47:54 EDT

14.00

+1.53

+12.27%

盘前13.74

-0.26-1.86%

07:47 EDT

High14.00	Low12.44	Vol1.43M
Open12.44	D1 Closing12.47	Amplitude12.51%
Mkt Cap801.65M	Tradable Cap580.03M	Total Shares57.26M
T/O19.18M	T/O Rate3.44%	Tradable Shares41.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":14,"timestamp":1786046400000,"preClose":12.47,"halted":0,"volume":1425530,"hourTrading":{"tag":"盘前","latestPrice":13.74,"preClose":14,"latestTime":"07:47 EDT","volume":352,"amount":4927.14992,"timestamp":1786103265260,"change":-0.26,"changeRate":-0.018571,"amplitude":0.118571},"delay":0,"changeRate":0.12269446672012825,"floatShares":41430600,"shares":57260500,"eps":-0.789373,"marketStatus":"Pre-Mkt","change":1.53,"latestTime":"08-07 07:47:54 EDT","open":12.44,"high":14,"low":12.44,"amount":19179553.89596,"amplitude":0.1251,"askPrice":14.88,"askSize":150,"bidPrice":13.73,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-0.789373,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1786109400000},"marketStatusCode":1,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":14,"preHourTrading":{"tag":"盘前","latestPrice":13.74,"preClose":14,"latestTime":"07:47 EDT","volume":352,"amount":4927.14992,"timestamp":1786103265260,"change":-0.26,"changeRate":-0.018571,"amplitude":0.118571},"postHourTrading":{"tag":"盘后","latestPrice":13.89,"preClose":14,"latestTime":"19:54 EDT","volume":14975,"amount":209585.71,"timestamp":1786060455107,"change":-0.11,"changeRate":-0.007857,"amplitude":0.007857},"volumeRatio":1.3111067334060649,"impliedVol":0.4772,"impliedVolPercentile":0.1103},"requestUrl":"/m/hq/s/CLYM/tweets","defaultTab":"tweets","newsList":[{"id":"2657617666","title":"Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), Kodiak Sciences (KOD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657617666","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657617666?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:30","pubTimestamp":1786051816,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Climb Bio (CLYM), Kodiak Sciences (KOD) and Viridian...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-climb-bio-clym-kodiak-sciences-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-climb-bio-clym-kodiak-sciences-kod-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM","BK4505","BK4139","BK4539","KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657300635","title":"Climb Bio Initiates Phase 2 Clym116 Trial in IgA Nephropathy in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657300635","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657300635?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:36","pubTimestamp":1786016201,"startTime":"0","endTime":"0","summary":"Climb Bio initiates Phase 2 CLYM116 trial in IgA nephropathy in Q3 2026Climb Bio flagged initial Phase 1 data for anti-APRIL antibody CLYM116 in healthy volunteers for presentation on Sept. 3, 2026.Ea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL23hq93:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633078","title":"Climb Bio Q2 EPS $(0.18) Beats $(0.21) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633078","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633078?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:33","pubTimestamp":1786016008,"startTime":"0","endTime":"0","summary":"Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 38.46 percent decrease over losses of $(0.13) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60989405/climb-bio-q2-eps-0-18-beats-0-21-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CLYM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657331716","title":"Climb Bio Q2 Net Loss Widens on Pipeline Advancement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657331716","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657331716?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:29","pubTimestamp":1786015790,"startTime":"0","endTime":"0","summary":"Climb Bio Q2 net loss widens on pipeline advancementOverviewUS biotechnology firm's Q2 net loss widened yr/yr as operating expenses increasedCompany completed $110 mln private placement, extending cas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","CLYM","DNTH","IBRN","BK4007","TYRA","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638294","title":"Climb Bio Q2 FY26 Net Loss Widens 55.73% to $13.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638294","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638294?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:11","pubTimestamp":1786014715,"startTime":"0","endTime":"0","summary":"Climb Bio Q2 FY26 net loss widens 55.73% to $13.5 millionClimb Bio posted a GAAP net loss of USD 13.5 million, widening from USD 8.67 million a year earlier.R&D expense rose to USD 9.71 million from U","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9WXQdp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657802366","title":"Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657802366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657802366?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014006,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA6PSZ0J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLYM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633913","title":"Climb Bio - Financing Extends Cash Runway into Second Half of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633913","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633913?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014006,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA6PSZ0J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLYM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680472","title":"Climb Bio Inc Q2 Income from Operations USD -15.359 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680472?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014006,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXP3D4KF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656308309","title":"Climb Bio Offers Compelling, Data-Rich H2 With Multiple Near-term Catalysts Across Two Programs, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2656308309","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656308309?lang=en_us&edition=fundamental","pubTime":"2026-08-03 23:40","pubTimestamp":1785771618,"startTime":"0","endTime":"0","summary":"Climb Bio  offers a compelling, data-rich H2, with several near-term catalysts across two differentiated programs in highly unmet need B-cell mediated diseases, RBC Capital Markets said in a Monday research note.RBC said that the proof-of-concept data for the company's Budoprutug anti-CD19 monoclonal antibody in primary membranous nephropathy from low dose has demonstrated early signals of efficacy, with recent immune thrombocytopenia data further de-risking the safety profile, suggesting Budoprutug can be dosed even higher.RBC said it sees out-year sales of about $700 million from Budoprutug across indications of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.RBC further said that the company's \"CLYM116 anti-APRIL mechanism is de-risked\" reflecting clinical and commercial validation, with sweeper Fc engineering potentially placing it competitively in the crowded IgA nephropathy market.RBC initiated its coverage on the company's stock with an ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLYM","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656276113","title":"Climb Bio Inc : RBC Initiates Coverage with Outperform Rating; Target Price $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2656276113","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656276113?lang=en_us&edition=fundamental","pubTime":"2026-08-03 17:46","pubTimestamp":1785750419,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN4400OJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","CLYM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655780472","title":"Climb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2655780472","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655780472?lang=en_us&edition=fundamental","pubTime":"2026-07-31 00:30","pubTimestamp":1785429047,"startTime":"0","endTime":"0","summary":"Climb Bio, Inc. ($CLYM) announced an update on their ongoing clinical study. Climb Bio, Inc. (CLYM) has completed a Phase 1 study called “A Phase 1...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/climb-bios-budoprutug-trial-completion-sets-stage-for-next-investor-catalyst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/climb-bios-budoprutug-trial-completion-sets-stage-for-next-investor-catalyst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654043887","title":"Climb Bio is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2654043887","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654043887?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:13","pubTimestamp":1785157980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings(END) Dow Jones NewswiresJuly 27, 2026 09:13 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654477012","title":"Wedbush Raises Price Target on Climb Bio to $20 From $17, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2654477012","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654477012?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:44","pubTimestamp":1785152683,"startTime":"0","endTime":"0","summary":"Climb Bio (CLYM) has an average rating of buy and mean price target of $21.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","CLYM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648852678","title":"Climb Bio Director Breanna Maurine Celebi Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2648852678","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648852678?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:25","pubTimestamp":1782937545,"startTime":"0","endTime":"0","summary":"Climb Bio director Breanna Maurine Celebi files initial beneficial ownership statementClimb Bio filed a Form 3 naming Breanna Maurine Celebi as a director, marking her initial Section 16 insider discl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL2xyx6R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648526669","title":"Climb Bio Names Breanna O’reilly to Board After Andrew Levin Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2648526669","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648526669?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:18","pubTimestamp":1782937101,"startTime":"0","endTime":"0","summary":"Climb Bio names Breanna O’Reilly to board after Andrew Levin resignsClimb Bio reshaped its board on June 29, 2026, following the resignation of director Andrew Levin, effective immediately.Breanna O'R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL5tgR0d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645889225","title":"Climb Bio Price Target Maintained with a $20.00/share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2645889225","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645889225?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:00","pubTimestamp":1782298800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings(END) Dow Jones NewswiresJune 24, 2026 07:00 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645707714","title":"Tango Therapeutics appoints Robert Azelby to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2645707714","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645707714?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:05","pubTimestamp":1782158746,"startTime":"0","endTime":"0","summary":"Tango Therapeutics appointed biopharmaceutical executive Robert Azelby to its board as it advances PRMT5 inhibitor vopimetostat toward potential late-stage pancreatic cancer development.Azelby previously led Eliem Therapeutics as CEO, ran Alder BioPharmaceuticals through its sale to H. Lundbeck, served as Juno Therapeutics’ chief commercial officer.He also spent 15 years at Amgen, ending as vice president and general manager of oncology overseeing a $6 billion portfolio.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLc0HXqp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CLYM","IE00BFTCPJ56.SGD","BK4539","LU1585245621.USD","LU0314104364.USD","LU0321505439.SGD","LU0225284248.USD","BK4139","BK4581","LU1718418525.SGD","IE00B2B36J28.USD","LU2125154935.USD","LU0432979614.USD","LU1868837300.USD","LU2360032135.SGD","IE0002141913.USD","NDAQ","BK4534","BK4559","TNGX","BK4599","LU1983299246.USD","BMY","LU1291159041.SGD","LU0306806265.USD","LU1868837136.USD","BK4566","LU1989771016.USD","LU1323610961.USD","LU1670711040.USD","LU0114720955.EUR","SG9999014005.SGD","LU0456855351.SGD","LU1093756325.SGD","LU0109394709.USD","LU1061106388.HKD","IE00BSNM7G36.USD","IE00BGHQF748.EUR","LU2210149790.SGD","AMGN","BK4112","IE00BFXG1179.USD","LU2125154778.USD","IE00B4R5TH58.HKD","LU2089984988.USD","IE00BN0W2T93.GBP","LU1093756168.USD","LU0985481810.HKD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643589213","title":"BRIEF-Climb Bio - Enters Open Market Sale Agreement With Jefferies - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2643589213","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643589213?lang=en_us&edition=fundamental","pubTime":"2026-06-13 05:01","pubTimestamp":1781298063,"startTime":"0","endTime":"0","summary":"BRIEF-Climb Bio - Enters Open Market Sale Agreement With Jefferies - SEC FilingJune 12  - Climb Bio Inc CLYM.O:CLIMB BIO - ENTERS OPEN MARKET SALE AGREEMENT WITH JEFFERIES - SEC FILINGCLIMB BIO - MAY OFFER AND SELL UP TO $100 MILLION OF COMMON STOCK - SEC FILINGSource text: [ID:n0001193125-26-269567]Further company coverage: CLYM.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nFWN42K0K8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643428218","title":"Climb Bio enters Jefferies ATM equity distribution agreement for up to $100 million stock sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2643428218","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643428218?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:37","pubTimestamp":1781296641,"startTime":"0","endTime":"0","summary":"Climb Bio entered an at-the-market equity distribution agreement with Jefferies for up to USD 100 million of common stock.Jefferies will act as sales agent with up to 3% commission on shares sold.The prior ATM program with Oppenheimer was terminated effective June 11, 2026; no shares were sold under that program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL1v9n1L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643185732","title":"Climb Bio - Enters Open Market Sale Agreement With Jefferies Dated June 12, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2643185732","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643185732?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:24","pubTimestamp":1781295874,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nFWN42K0P3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eliemtx.com","stockEarnings":[{"period":"1week","weight":0.1589},{"period":"1month","weight":0.0432},{"period":"3month","weight":0.2313},{"period":"6month","weight":1.5735},{"period":"1year","weight":7},{"period":"ytd","weight":2.5}],"compareEarnings":[{"period":"1week","weight":0.0362},{"period":"1month","weight":0.0279},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.1129},{"period":"1year","weight":0.2146},{"period":"ytd","weight":0.1271}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.012175},{"month":2,"riseRate":0.6,"avgChangeRate":0.088588},{"month":3,"riseRate":0.2,"avgChangeRate":-0.090224},{"month":4,"riseRate":0.8,"avgChangeRate":0.28834},{"month":5,"riseRate":0.6,"avgChangeRate":0.068848},{"month":6,"riseRate":0.4,"avgChangeRate":-0.017955},{"month":7,"riseRate":0.6,"avgChangeRate":0.043539},{"month":8,"riseRate":0.4,"avgChangeRate":0.112717},{"month":9,"riseRate":0.2,"avgChangeRate":-0.124516},{"month":10,"riseRate":0.4,"avgChangeRate":-0.049478},{"month":11,"riseRate":0,"avgChangeRate":-0.130257},{"month":12,"riseRate":0.6,"avgChangeRate":0.177771}],"exchange":"NASDAQ","name":"CLIMB BIO INC","nameEN":"CLIMB BIO INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CLIMB BIO INC(CLYM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CLIMB BIO INC,CLYM,CLIMB BIO INC股票,CLIMB BIO INC股票老虎,CLIMB BIO INC股票老虎国际,CLIMB BIO INC行情,CLIMB BIO INC股票行情,CLIMB BIO INC股价,CLIMB BIO INC股市,CLIMB BIO INC股票价格,CLIMB BIO INC股票交易,CLIMB BIO INC股票购买,CLIMB BIO INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CLIMB BIO INC(CLYM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction